•
NB
NBIX
Neurocrine Biosciences Inc
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
13.50B
Volume
927.09K
52W High
$160.18
52W Low
$84.23
Open
$0.00
Prev Close
$134.54
Day Range
0.00 - 0.00
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Latest News
Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage
Benzinga•Dec 23
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
The Motley Fool•Dec 4
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
GlobeNewswire Inc.•Aug 8
Neurocrine (NBIX) Q2 Revenue Jumps 17%
The Motley Fool•Aug 1
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
GlobeNewswire Inc.•Jul 16
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
GlobeNewswire Inc.•Jun 2
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
GlobeNewswire Inc.•May 28
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
GlobeNewswire Inc.•May 2